12:21 PM EDT, 10/01/2024 (MT Newswires) -- Eli Lilly ( LLY ) is considering testing its weight-loss drugs on individuals who are not overweight but are at risk of gaining weight or might develop conditions like stroke or diabetes, the Financial Times reported Tuesday, citing the company's Chief Executive David Ricks.

The CEO said the body mass index or BMI thresholds of its studies on weight-loss drugs could be lowered, particularly in certain populations where the cut-off is not appropriate for disease prevention, according to the news outlet.

The Chief Executive said Eli Lilly's ( LLY ) studies have a BMI cut-off point of at least 27 but the weight-loss drugs could also be used by people with a BMI of below 25, aiming to reduce the chances of developing diabetes, vascular dementia, or other conditions.

Ricks also said the company could look into the use of anti-obesity medications for health maintenance in the long term, according to the news outlet.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 882.76, Change: -3.18, Percent Change: -0.36